Migraine, nouveautés thérapeutiques et recommandations : comment j’adapte la prise en charge au quotidien ?

Demarquay, 2021, Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 1: diagnosis and assessment, Rev Neurol (Paris), 177, 725, 10.1016/j.neurol.2021.07.001 Ducros, 2021, Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: pharmacological treatment, Rev Neurol (Paris), 177, 734, 10.1016/j.neurol.2021.07.006 Demarquay, 2021, Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 3: non-pharmacological treatment, Rev Neurol (Paris), 177, 753, 10.1016/j.neurol.2021.07.009 Kurth, 2020, Association of migraine with aura and other risk factors with incident cardiovascular disease in women, JAMA, 323, 2281, 10.1001/jama.2020.7172 Donnet, 2021, Severe migraine and its control: a proposal for definitions and consequences for care, Rev Neurol (Paris), 177, 924, 10.1016/j.neurol.2020.11.012 Bjørk, 2022, Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability, JAMA Neurol, 79, 672, 10.1001/jamaneurol.2022.1269 Dodick, 2010, OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program, Headache, 50, 921, 10.1111/j.1526-4610.2010.01678.x